Roche Halts SKYSCRAPER-06 Lung Cancer Drug Trial After Failing to Show Benefit

Jul 4, 2024, 08:03 AM

Roche has announced the termination of its Phase II/III SKYSCRAPER-06 clinical trial for metastatic non-squamous non-small cell lung cancer. The trial, which combined the PD-L1 inhibitor atezolizumab with the TIGIT inhibitor tiragolumab and chemotherapy, failed to demonstrate a significant benefit in overall survival (OS) and progression-free survival (PFS) compared to the control group. The hazard ratios for OS and PFS were 1.33 and 1.27, respectively, with 95% confidence intervals. This decision marks a significant setback for Roche's lung cancer immunotherapy efforts, particularly in comparison to established treatments like Merck's Keytruda. The trial was conducted under the ticker $RHHBY.